Retatrutide + Cagrilintide (GLP-1 Fat-Loss Stack)

This isn't one drug, it's a category of "stack two appetite drugs" combos that get lumped together online. The legitimate, productised version is CagriSema: cagrilintide (a long-acting amylin analogue) plus semaglutide (the GLP-1 in Ozempic/Wegovy), combined in one injection by Novo Nordisk and put through the Phase 3 REDEFINE trial programme. The biohacker version swaps semaglutide for retatrutide, Eli Lilly's triple agonist (GLP-1 + GIP + glucagon), and runs it alongside cagrilintide bought separately as "research peptides". The amylin angle is the same in both: amylin is a satiety hormone the pancreas releases after meals, and the pitch is that you layer that fullness signal on top of the GLP-1 machinery.

The sales story is "two mechanisms beat one". CagriSema reached around 20-23% mean weight loss at 68 weeks in REDEFINE 1 (about 20% on the conservative treatment-policy estimate, ~23% in people who stayed on it), beating semaglutide or cagrilintide alone. Retatrutide on its own has posted some of the biggest weight-loss numbers in the field — roughly 24% at 48 weeks in its Phase 2 trial, and around 28% at 80 weeks in its first Phase 3 readout (TRIUMPH-1, reported in 2026) — which is why headlines keep calling it the "triple agonist" or "Ozempic killer". Grey-market sellers take those separate trial figures and splice them into a promise that reta + cagri will out-lose everything, marketing it as the strongest fat-loss shot you can stack.

Split the two versions, because the honesty depends on which one you mean. CagriSema (semaglutide + cagrilintide) actually has Phase 3 human trials behind it — semaglutide is Grade A, cagrilintide and the CagriSema combo are Grade B, and Novo filed for approval in late 2025. That's real evidence. The retatrutide + cagrilintide combo that biohackers buy is a different animal: no clinical trial has ever tested those two together. Retatrutide and cagrilintide are each Grade B as investigational drugs, and the "stack" is purely mechanistic guesswork copied from the CagriSema results. And notice the gap — the people selling reta + cagri vials are selling unlicensed powder, then handing you trial numbers from a completely different (semaglutide-based) product to justify it. The GI side effects are real and dose-related even in the supervised trials; doing this yourself with unregulated peptides removes every safety net those trials had.

Neither retatrutide nor cagrilintide is a licensed medicine in the UK — both are still in clinical trials, with no MHRA or EMA approval, so they can't legally be prescribed or dispensed here, on the NHS or privately. Semaglutide (Wegovy/Ozempic) is licensed; CagriSema is not — Novo Nordisk filed for US approval in late 2025, but it carries no UK marketing authorisation yet, with regulatory decisions still playing out through 2026. Anything sold now as "reta", "cagri" or a "fat-loss stack" is an unlicensed research chemical with no MHRA check on what's actually in the vial. The only regulated UK access to these investigational drugs is via a registered clinical trial.